Tap Global Group plc (TAP), the regulated crypto-fintech, provides its first regular monthly update on its proprietary crypto yield generating platform, Tap Earn, for the month of October 2026. Tap Earn pays customers and Tap’s own Digital Asset Income Strategy treasury a weekly return on eligible crypto balances.
October Key Performance Indicators
Net asset inflows: c.US$1.45 million (September: c.US$0.97 million)
AUM at 31 October: c.US$9.13 million (30 September: c.US$8.45 million)
Gross yield*: c.5.6% annualised (September: c.5.4%)
Cumulative gross yield since launch in May 2026: c.6.7% annualised
Comment: Given the crash in cryptos in November to date, it is perhaps of more interest how TAP’s yield generation platform – a decent concept – will do when the underlying asset is falling like a stone. At least the company has progressed from the buy and hope Bitcoin Treasury concept. Oh yes, and the share price below 1p - not good.
Gear4music (G4M), the largest UK based online retailer of musical instruments and music equipment, today announces its unaudited financial results for the six months ended 30 September 2026. FY27 Q3 revenue to date down 13% year on year, but 19% ahead of the equivalent period in FY25. Lower paid-search traffic driving weaker trading, partly reflecting more prominent AI-generated results. Expanding advertising within AI search and improving website visibility expected to support recovery over time. FY27 EBITDA now expected to be approximately £11.5m, significantly below current consensus market expectations.
Comment: Just when one might have thought that G4M was immune to the slings and arrows of the UK economy, and the cost of living (taxation) crisis, it shows in today’s profits warning, that it is just as mortal as the rest of us. That said, those musical instruments do not come cheap.
Somero Enterprises, Inc. (SOM) announces that, following continued positive trading since its interim results in September 2026, for the full year ending 31 December 2026, the Board now expects: Revenue of approximately US$100m (previous guidance: US$95m). Adjusted EBITDA of approximately US$20.5m (previous guidance: US$19.5m). Year-end net cash of approximately US$34.0m, assuming US$2.0m of the additional US$6.0m share repurchase authorization is executed prior to year-end (previous guidance: US$29m, which assumed the full US$6.0m was executed). Activity has been supported in part by AI-related data center construction in the US, alongside stabilization in other private non-residential construction markets. Customers continue to report healthy levels of activity and good visibility of work into 2027. The Company’s backlog for November and December remains robust, giving the Board confidence in the outcome for the year.
Comment: After the gut punch of the G4M update, it is perhaps something of a relief to look at SOM and see all the robust metrics on display. What is interesting here is that the market has only caught onto the merits of the company in share price terms since July, so there may be more to come on the upside, once today’s update is absorbed.
Cobra (COBR), a South Australian mineral exploration and development company advancing the Wudinna Rare Earth Project and the Manna Hill Copper Project, announced a conditional fundraise of £2.0 million pursuant to a direct subscription with certain existing shareholders and a subscription by Andrew Michelmore AO, Non-Executive Chairman of the Company. The net proceeds of the Subscription will be used to: fund drilling, assays and geological target definition at the Manna Hill Copper Project; advance the Wudinna Rare Earth Project, including procurement, construction and operation of a small scale production study; and provide general working capital and meet corporate costs.
Comment: With just a month or so to go to Christmas, we are getting, or are going to get, companies raising money to pay for Santa’s presents. In the case of COBR one could see the raise coming, not least from the share price dip since September, as well as the tone of recent RNS updates. The question is how long the £2m will last?
Critical Metals plc (CRTM), a mining company established to acquire mining opportunities in the critical and strategic metals sector, announces the completion of its Acid-Soluble Copper (Preliminary Test Programme) at the Molulu Copper/Cobalt Project. The programme confirmed 74% copper recovery from stockpile and supports further exploration and studies to develop Molulu. The programme reflects the Company’s collaboration with a potential offtake partner to test a total of circa 300 kilograms (kg) of ore from existing stockpiles, blended to form a head grade of 1.43% Total Copper (TCu).
Comment: It has been a stellar and surprising mega-rally we have been treated to at CRTM, something which even though it is fully justified in the wake of today’s news has been met with some profit taking. That said, shareholders will surely be over the moon in the wake of the re-rate so far.
The Smarter Web Company (SWC) announces the purchase of additional Bitcoin as part of “The 10 Year Plan” which includes an ongoing treasury policy of acquiring Bitcoin. Details are as follows: Number of Bitcoin Purchased: 55 Bitcoin. Average Purchase Price: £49,991 per Bitcoin. Amount Purchased: £2,749,500.
Comment: More “buy and hope” purchasing of BTC with the PLC costs, in the hope that $64k is the low, as opposed to $126k being the all time high. While the 10 Year Plan sounds worthy, do we believe either BTC or SWC will be around in their current form in ten years?
CRISM Therapeutics Corporation (CRTX) , a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announced that the first patient has been successfully treated with its proprietary irinotecan ChemoSeed® implant as part of the Company's registration grade Phase II clinical trial in patients with glioblastoma. This represents a significant milestone for CRISM Therapeutics, marking the commencement of clinical data generation for its lead oncology asset and the first step towards establishing the safety and efficacy profile of ChemoSeed® in a disease with significant unmet medical need.
Comment: Given how long and how expensive the process of drug development seems to be at companies such as Avacta (AVCT), one might have thought that the market would be jumping for joy in the wake of the latest news from CRTX. This is not quite the case. But then again it is early days.
GenIP plc (GNIP) , a provider of AI-driven services to help research organisations and corporations commercialise their innovations, provides an update on the soft launch of its Invention Evaluator Platform as announced on the 19 October 2026.
Successful Soft Launch
Several customers have now successfully trialled the Platform and initial feedback has been positive, with customers preferring the Platform’s new features and its streamlined, action-oriented approach to managing and prioritising technologies. During the trial, the Company identified 17 pilot accounts across several international markets and has already begun initial commercial discussions about migrating them to the new Platform including a significant customer from 2025, who has already agreed to initiate the migration plan as an early adopter. Based on this early feedback, management believes the pilot accounts alone could represent a potential annual subscription value of around US$170,000 in aggregate.
Comment: GNIP continues to finesse / strengthen the offering, all in the name of increasing revenues, something which is needed sooner rather than later. It is commendable that the latest initiative is on track, with the only wish being that one could add a zero to the end of the $170k number.


